According to the latest report published on the healthcare entity’s website, 5,206,801 people have received a first dose of Abdala, Soberana 02 or Soberana Plus vaccines.

With a second dose administered, there are 4,481,406 people, and with complete vaccination schemes in three doses the figure reaches 3,165,387.

Lately, Cuba’s drug regulatory entity authorized the Abdala, Soberana 02 and Soberana Plus formulas for mass emergency use, making Cuba the first country in Latin America to develop vaccines against Covid-19.

Abdala, created by the Center for Genetic Engineering and Biotechnology (CIGB), has a three-injection immunization scheme and in 3rd Phase clinical trials in adult population had 92.28 percent efficacy, and 100 percent against severity and death.

Meanwhile, Soberana 02, designed by the Finlay Vaccine Institute (IFV) and Soberana Plus, from the same center, showed 91.2 percent efficacy in the 3rd Phase trials.

Its heterologous scheme, of two doses of Soberana 02 adding one of Soberana Plus, also proved 100 percent efficacy against severe symptomatology and death.

Cuba has other proposals against Covid-19: Soberana 01, from IFV; and Mambisa, from CIGB, the latter being a nasally administered formulation, which has already been authorized by the regulatory entity for its 1st and 2nd Phase clinical trial in 120 convalescent volunteers, along with the Abdala vaccine.

ef/omr/mgt/ghp